9 Deer Park Drive
United States - Map
Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The companys Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.
|Insmed Incorporated’s ISS Governance QuickScore as of Dec 1, 2013 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 9; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. William H. Lewis ,
Chief Exec. Officer, Pres and Director
|Mr. Andrew T. Drechsler ,
Chief Financial Officer and Principal Accounting Officer
|Ms. Renu Gupta M.D.,
Chief Medical Officer and Exec. VP of Devel.
|Mr. Walter Perkins Ph.D.,
Chief Technology Officer
|Ms. Christine A. Pellizzari ,
Gen. Counsel and Corp. Sec.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|